Blanket Purchase Agreement 36F79721D0170-36E79722A0004
Award Date
10/15/21
Last Date to Order
10/14/25
Federal Agency
National Acquisition Center
Awardee
Biomarin Pharmaceutical Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract to BioMarin Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, under GSA Schedule 61-IB for Pharmaceuticals and Drugs. The contract has a ceiling value of $3,139,060 and runs through June 2026. Under this FSS contract, the VA has issued several delivery orders and a $151,685 Blanket Purchase Agreement (BPA) to procure the drug Palynziq (pegvaliase-pqpz) from BioMarin. The delivered Palynziq is...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, which is a civilian agency under the Department of Veterans Affairs (VA), to Marius Pharmaceuticals LLC, a self-certified small disadvantaged business. The BPA has a ceiling value of $1,406.70 and a period of performance through March 2026. The purpose of this BPA is to facilitate the procurement of the pharmaceutical product KYZATREX by VA medical centers nationwide. Marius Pharmaceuticals, which holds a...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Marius Pharmaceuticals LLC, a self-certified small disadvantaged business organized as a limited liability company. The BPA has a ceiling value of $10,000,000 and a period of performance through January 31, 2024. The primary purpose of this BPA is to facilitate the procurement of a specific pharmaceutical product called KYZATREX by the Department of Veterans Affairs (VA) and its...
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a $883,061.15 Blanket Purchase Agreement (BPA) to Albireo Pharma, Inc. to provide the drug Bylvay under the Pharmaceuticals and Drugs GSA Schedule. This single-award BPA, effective from April 2022 through March 2026, facilitates task order delivery of Bylvay to VA medical centers nationwide. Bylvay is used to treat the rare disease progressive familial intrahepatic cholestasis. Additionally, Albireo Pharma holds a...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Akebia Therapeutics, Inc. as a single-award contract under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The BPA has a ceiling value of $10,254,764.65 and a period of performance from April 25, 2025 to April 24, 2026. The purpose of this BPA is to provide the VA with the pharmaceutical products VAFSEO and AURYXIA. No set-asides were used for this award....
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Genentech USA, Inc. for the procurement of Evrysdi. The BPA has a potential value of $1 million and a period of performance from March 12, 2021 through September 14, 2023, with four one-year option periods. The BPA was established against the Pharmaceuticals and Drugs GSA Schedule and provides a contracting vehicle for ordering Evrysdi to treat spinal muscular atrophy. Spinal muscular...
The Department of Veterans Affairs National Acquisition Center has awarded a Blanket Purchase Agreement (BPA) to Alexion Pharmaceuticals Inc. (doing business as Alexion) under the Pharmaceuticals and Drugs GSA Schedule. The single-award BPA has a potential value of $4,239,517.80 and a period of performance from September 1, 2022 through August 31, 2025. The purpose of this BPA is to allow VA medical centers and clinics nationwide to place orders for the drug Strensiq to treat patients with...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to CSL Behring L.L.C., a global biotherapeutics company that provides specialty pharmaceutical products to the VA. The BPA has a ceiling value of $17,500,000 and allows VA facilities nationwide to efficiently order the medication HAEGARDA, a C1 inhibitor treatment for hereditary angioedema, as needed through September 2025. The VA Greater Los Angeles Healthcare System...